PPDI Insider Trading Activity and SEC Form 4 Filings
PPDI insider trading summary
No open-market insider purchases or sales of Pharmaceutical Product Development Inc (PPDI) have been reported on SEC Form 4 in the past 12 months.
Latest PPDI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 27, 2011 | Paul Colvin | EVP--Clinical Development | Sell | $162K (5,659 @ $28.70) |
| May 26, 2011 | Paul Colvin | EVP--Clinical Development | Sell | $3K (100 @ $28.70) |
| May 20, 2011 | Paul Colvin | EVP--Clinical Development | Sell | $17K (600 @ $29.01) |
| May 3, 2011 | Judd Hartman | General Counsel | Sell | $3.4M (112,476 @ $30.23) |
| Mar 1, 2011 | Fred Frank | Director | Sell | $228K (8,281 @ $27.55) |
| Mar 1, 2011 | Terry Magnuson | Director | Sell | $229K (8,281 @ $27.70) |
| Feb 28, 2011 | David L Grange | Chief Executive Officer | Sell | $897K (34,501 @ $26.00) |
| Feb 28, 2011 | Michael O. Wilkinson | Chief Information Officer | Sell | $611K (21,667 @ $28.19) |
| Feb 14, 2011 | Michael O. Wilkinson | Chief Information Officer | Sell | $706K (24,496 @ $28.84) |
| Nov 3, 2010 | David L Grange | Chief Executive Officer | Sell | $1.3M (51,380 @ $25.71) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.